Altimmune, Inc. ALT · NASDAQ
$2.12 -2.30% (-$0.05)
Summary
33 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $63.1M against $35.7M.
- It beat profit estimates 7 times in the last 8 quarters.
What to watch
- The company made a loss over the last 12 months.
- Analysts expect revenue to fall by 95% this fiscal year.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 65% a year over 5 years. For the next fiscal year analysts expect revenue to fall by 95%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $91.8M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 12
- Hold 3
- Sell 0
Today's price within the analysts' price targets
The average target of $6.25 is 195% above today's price. 80% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2021By product
- Grant 100%
By region
The company reports no revenue by region.
Grant brings in 100% of revenue.
Segments in detail